Also found in: Dictionary.


Apo-Meloxicam (CA), Co Meloxicam (CA), Dom-Meloxicam (CA), Gen-Meloxicam (CA), Mobic, Mobicox (CA), Novo-Meloxicam (CA), PHL-Meloxicam (CA), Ratio-Meloxicam (CA)

Pharmacologic class: Nonopioid analgesic, nonsteroidal anti-inflammatory drug (NSAID)

Therapeutic class: Analgesic, anti-inflammatory drug

Pregnancy risk category C

FDA Box Warning

• Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke. Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for it may be at greater risk.

• Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation. These events can occur at any time during use and without warning. Elderly patients are at greater risk.

• Drug is contraindicated for treatment of perioperative pain in setting of coronary artery bypass graft surgery.


Unknown. Thought to reduce inflammation and pain by inhibiting prostaglandin synthesis of the enzyme cyclooxygenase.


Oral suspension: 7.5 mg/5 ml

Tablets: 7.5 mg, 15 mg

Indications and dosages

Osteoarthritis; rheumatoid arthritis

Adults: 7.5 mg P.O. once daily; may increase to 15 mg/day

Juvenile arthritis

Children ages 2 and older: 0.125 mg/kg P.O. once daily, up to a maximum of 7.5 mg


• Hypersensitivity to drug, its components, or other NSAIDs


Use cautiously in:

• bleeding disorders, GI or cardiac disorders, severe renal impairment, severe hepatic disease, asthma, peptic ulcer disease

• concurrent aspirin, oral anticoagulant, or corticosteroid therapy

• elderly or debilitated patients

• pregnant or breastfeeding patients.


• Before starting therapy, ask patient about aspirin sensitivity and allergies to other NSAIDs. If patient is dehydrated, provide adequate fluids.

Adverse reactions

CNS: headache, dizziness, syncope, malaise, fatigue, asthenia, depression, confusion, nervousness, drowsiness, insomnia, vertigo, tremor, paresthesia, anxiety, seizures

CV: hypertension, hypotension, palpitations, angina, vasculitis, heart failure, arrhythmias, MI

EENT: abnormal vision, conjunctivitis, hearing loss, tinnitus, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, colitis, GI ulcers with perforation, abdominal pain, dyspepsia, gastroesophageal reflux, esophagitis, flatulence, ulcerative stomatitis, dry mouth, pancreatitis, GI hemorrhage

GU: urinary frequency, urinary tract infection, albuminuria, hematuria, renal failure

Hematologic: anemia, purpura, leukopenia, thrombocytopenia

Hepatic: hepatitis

Musculoskeletal: joint pain, back pain

Metabolic: dehydration

Respiratory: upper respiratory infection, dyspnea, coughing, asthma, bronchospasm

Skin: rash, urticaria, pruritus, bullous eruption, sweating, alopecia, photosensitivity, angioedema

Other: altered taste, increased appetite, weight gain or loss, hot flashes, fluid retention and edema, masking of infection symptoms, hypersensitivity reactions including anaphylaxis


Drug-drug. Angiotensin-converting enzyme inhibitors: decreased antihypertensive effect

Anticoagulants: increased risk of bleeding

Aspirin: increased meloxicam blood level, increased risk of toxicity

Cholestyramine: decreased meloxicam blood level

Furosemide, thiazides: decreased diuretic effect

Lithium: increased lithium blood level

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, gamma-glutamyl transferase: increased levels

Hemoglobin, platelets, white blood cells: decreased values

Drug-behaviors. Alcohol use, smoking: increased risk of GI irritation and bleeding

Patient monitoring

Closely monitor patient with aspirin-sensitivity asthma, because of risk of severe bronchospasm.

• In prolonged therapy, monitor CBC and kidney and liver function tests.

Assess for cardiovascular disorders and hepatotoxicity.

• Monitor patient for fluid retention and weight gain.

Patient teaching

Instruct patient to immediately report signs and symptoms of hepatotoxicity, including right upper quadrant pain, nausea, fatigue, lethargy, pruritus, and jaundice.

• Tell patient to report abdominal pain, blood in stool or emesis, or black tarry stools.

• Instruct patient to avoid alcohol and smoking.

• Caution pregnant patient to avoid drug, especially during third trimester.

• Tell patient to consult prescriber before taking over-the-counter preparations.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.


A trademark for the drug meloxicam.


An oral NSAID used for osteoarthritis.
Mentioned in ?
References in periodicals archive ?
The proposed algorithm outperforms new ALM and MOBIC clustering algorithms.
From Figure 7, it can be seen that the number of clusters formed using HCA surpasses the number of clusters formed using the SCBC, DDVC, DLDC, MPBC, and MOBIC schemes.
Pooling resources allowed companies like AffordRx to offer steep discounts with Mobic coupons and more, helping patients who could not otherwise afford their medication.
2 mg for hypertension; during hemodialysis, Epogen 2200 units IV, Fosrenol 1000 mg, Heparin 6000 units IV; Lisinopril 10 mg and Minoxidil 10 mg for hypertension; Mobic 7.
Her health history also reveals that she has high blood pressure for which she takes Monopril and osteoarthritis in her left hip for which takes Mobic.
During the same period, medical journal advertising for plain anti-arthritis treatments grew by 360 percent, again led by Mobic in an aggressive bid for the top spot.
Among Rx brands, again, Mobic, an antiarthritis drug from Boehringer Ingelheim Pharmaceuticals Inc.
The health-care and drugs firm's profit was helped by increased revenues from its treatments for arthritis: Sales of Mobic tripled after Bextra, a rival drug from Pfizer, was withdrawn on safety grounds.
India appears to be at the forefront of the developing market for mobile phone (and data) services to young people, according to the Website mobic.
COX-2 specific inhibitors (cyclooxygenase inhibitors), are a fairly new class of NSAIDs that include celecoxib (Celebrex), valdecoxib (Bextra) and mobic (Meloxicam).
The medications are celecoxib (Celebrex) approved to treat osteoarthritis and rheumatoid arthritis and mobic (Meloxicam) approved for osteoarthritis.
Also new are Mobic (number 24) and Endocet (number 25)--both non-steroidal anti-inflammatory drugs.